Pharmacovigilance in the pharmaceutical industry
- 1 May 1998
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 45 (5), 427-431
- https://doi.org/10.1046/j.1365-2125.1998.00713.x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- End of the line for “third-generation-pill” controversy?The Lancet, 1997
- The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational researchContraception, 1996
- Concepts in Risk-Benefit Assessment A Simple Merit Analysis of a Medicine?Drug Safety, 1996
- Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysisBMJ, 1996
- Pharmacovigilance education and certification report on a feasibility surveyPharmacoepidemiology and Drug Safety, 1995
- Guidelines for company‐sponsored Safety Assessment of Marketed Medicines (SAMM) guidelines. Medicines Control Agency, Committee on Safety of Medicines, Royal College of General Practitioners, British Medical Association and Association of the British Pharmaceutical Industry (November 1993) [see comments]British Journal of Clinical Pharmacology, 1994
- The Way Towards Adverse Event Monitoring in Clinical TrialsDrug Safety, 1993
- Review of company postmarketing surveillance studies.BMJ, 1992
- Study of United Kingdom product licence applications containing new active substances, 1987-9.BMJ, 1991
- The case for recording events in clinical trials.BMJ, 1977